氯吡格雷联合阿司匹林与单用阿司匹林在TIA或轻型卒中后大出血风险的比较:POINT试验二次分析
该研究为POINT随机双盲试验的二次分析,纳入4881例高风险TIA或轻型AIS患者,随机接受氯吡格雷加阿司匹林或安慰剂加阿司匹林,随访90天。按治疗分析显示,联合组大出血发生率为0.9%,单用阿司匹林组为0.2%,风险比为3.57,联合治疗虽增加出血风险但总体发生率低。
要点
- 氯吡格雷联合阿司匹林较单用阿司匹林显著增加大出血风险。
- 联合组大出血发生率为0.9%,单用组为0.2%。
- 两方案大出血绝对风险均较低,但需权衡获益与出血风险。
核心结论
- 在TIA或轻型AIS患者中,氯吡格雷联合阿司匹林较单用阿司匹林增加大出血风险,从0.2%升至0.9%,但总体大出血风险较低。
研究设计与样本
- POINT随机双盲临床试验的二次分析,在10个国家269个中心纳入4881例高风险TIA或轻型AIS患者,随机分配至氯吡格雷加阿司匹林组或安慰剂加阿司匹林组,随访90天。
主要发现
- 致死性出血4例(0.1%),其中联合组3例、单用组1例;颅内出血7例(0.1%),联合组5例、单用组2例。
- 大出血最常见部位为胃肠道。
临床怎么用
- 对于高风险TIA或轻型AIS患者,使用氯吡格雷联合阿司匹林时应评估出血风险,尤其关注消化道出血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone. OBJECTIVE: To characterize the frequency and kinds of major hemorrhages in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) trial. DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis of the POINT randomized, double-blind clinical trial conducted in 10 countries in North America, Europe, and Australasia included patients with high-risk TIA or minor AIS who were randomized within 12 hours of symptom onset and followed up for 90 days. The total enrollment, which occurred from May 28, 2010, through December 17, 2017, was 4881 and constituted the intention-to-treat group; 4819 (98.7%) were included in the as-treated analysis group. The primary safety analyses were as-treated, classifying patients based on study drug actually received. Intention-to-treat analyses were performed as secondary analyses. Data were analyzed in April 2018. INTERVENTIONS: Patients were assigned to receive clopidogrel (600 mg loading dose on day 1 followed by 75 mg daily for days 2-90) or placebo; all patients also received open-label aspirin, 50 to 325 mg/d. MAIN OUTCOMES AND MEASURES: The primary safety outcome was all major hemorrhages. Other safety outcomes included minor hemorrhages. RESULTS: A total of 269 sites worldwide randomized 4881 patients (median age, 65.0 years [interquartile range, 55-74 years]; 2195 women [45.0%]); the primary results have been published previously. In the as-treated analyses, major hemorrhage occurred in 21 patients (0.9%) receiving clopidogrel plus aspirin and 6 (0.2%) in the aspirin alone group (hazard ratio, 3.57; 95% CI, 1.44-8.85; P = .003; number needed to harm, 159). There were 4 fatal hemorrhages (0.1%; 3 in the clopidogrel plus aspirin group and 1 in the aspirin alone group); 3 of the 4 were intracranial. There were 7 intracranial hemorrhages (0.1%); 5 were in the clopidogrel plus aspirin group and 2 in the aspirin plus placebo group. The most common location of major hemorrhages was in the gastrointestinal tract. CONCLUSIONS AND RELEVANCE: The risk for major hemorrhages in patients receiving either clopidogrel plus aspirin or aspirin alone after TIA or minor AIS was low. Nevertheless, treatment with clopidogrel plus aspirin increased the risk of major hemorrhages over aspirin alone from 0.2% to 0.9%. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00991029.
引用
- Tillman H, Johnston SC, Farrant M, et al. Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. JAMA Neurol. 2019. PMID: 31034032. doi:10.1001/jamaneurol.2019.0932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。